Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. reports developments in bioelectronic medicine and wellness products built around non-invasive vagus nerve stimulation, or nVNS. Company news commonly covers prescription gammaCore for migraine, Quell Fibromyalgia, Truvaga and Truvaga Plus consumer wellness products, and TAC-STIM for human performance.
Recurring updates include financial results, U.S. prescription sales activity, direct-to-consumer wellness sales, product-line commercialization, clinical research involving gammaCore nVNS, and participation in healthcare and investor conferences. News also highlights applications of vagus nerve stimulation across prescription medical uses and consumer wellness settings.
electroCore (Nasdaq: ECOR) reported a record revenue of approximately $8.5 million for the full year 2022, marking a 57% increase from 2021. The company also achieved $2.5 million in revenue for the fourth quarter, a 68% growth year-over-year. Key revenue drivers included about $5.1 million from government channels, showing a 56% growth compared to 2021, and $1.7 million from U.S. commercial channels, reflecting a 158% increase. The firm ended 2022 with approximately $18.0 million in cash and equivalents, down from $21.9 million in Q3.
electroCore, Inc. (Nasdaq: ECOR) has launched a new wellness product, TruvagaTM, available in the U.S. via its ecommerce site, www.truvaga.com. This handheld, non-invasive vagus nerve stimulator is designed to promote general wellbeing through stress reduction, requiring only two-minute sessions without the need for apps or chargers. CEO Dan Goldberger emphasized that Truvaga is part of the company's strategy to enhance accessibility to vagus nerve stimulation technology. This move aligns with electroCore's focus on improving health outcomes through innovative therapies.
electroCore (Nasdaq: ECOR) announced the issuance of two new patents by the USPTO, enhancing its non-invasive vagus nerve stimulation (nVNS) technology. The first patent, U.S. Patent No. 11,511,109, relates to treating gastroparesis and functional dyspepsia with nVNS methods. The second patent, U.S. Patent No. 11,517,742, covers devices and methods for treating various disorders using nVNS. CEO Dan Goldberger highlighted that these patents broaden the application of nVNS therapy beyond migraines and cluster headaches, reflecting the company's commitment to innovation.
electroCore, Inc. (NASDAQ: ECOR) announced that its gammaCore Sapphire device has received a National Code Number (CNK) in Belgium. This unique identifier, issued by the Belgian Pharmaceutical Association, will facilitate the availability of gammaCore in pharmacies across Belgium. Iain Strickland, Senior Vice President at electroCore, emphasized that this development enhances patient access to their innovative vagus nerve stimulation therapy, which is used to treat various headache conditions. gammaCore is FDA cleared in the U.S. and CE-marked in the EU for several indications.
electroCore, Inc. (Nasdaq: ECOR) announced that CEO Dan Goldberger will hold one-on-one meetings at the Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum on November 17, 2022. electroCore focuses on bioelectronic medicine, aiming to enhance patient outcomes through non-invasive vagus nerve stimulation therapy. Their current treatments address several neurological conditions, including cluster headaches and migraines.
electroCore, Inc. (Nasdaq: ECOR) reported a 33% increase in third quarter 2022 revenue, totaling approximately $2.0 million, compared to $1.5 million in Q3 2021. Net loss widened to $5.5 million, up from $4.0 million year-over-year. Gross profit improved to $1.7 million with a gross margin of 87%, up from 76%. Total operating expenses rose to $7.3 million, up from $5.1 million. The company anticipates Q4 2022 revenue between $2.2 million and $2.3 million with cash usage of $4.0 million to $4.5 million.
electroCore (Nasdaq: ECOR) announced a distribution agreement with Joerns Healthcare to exclusively distribute the gammaCore Sapphire™, an FDA-cleared non-invasive device for treating headache pain. This collaboration aims to enhance patient access in managed care health systems and streamline billing processes. Joerns Healthcare's role is expected to facilitate broader usage of gammaCore therapy, benefiting primary headache sufferers. With this partnership, electroCore looks to expand its market presence and improve patient outcomes in the neurology sector.
electroCore, Inc. (Nasdaq: ECOR) has announced a strategic partnership with Joerns Healthcare for the distribution and billing of gammaCore Sapphire™, an FDA-cleared device for treating various headache types via vagus nerve stimulation. Joerns, known for streamlining healthcare delivery, aims to enhance access to electroCore's therapy within managed care systems. This collaboration is positioned to expand usage among patients suffering from primary headaches, aligning with electroCore's mission of improving patient outcomes using non-invasive treatments.
electroCore, Inc. (Nasdaq: ECOR) will release its third quarter financial results on November 3, 2022, after market hours. A conference call and webcast will follow at 4:30 PM EDT to discuss the results. The company focuses on bioelectronic medicine, utilizing non-invasive vagus nerve stimulation therapy for treating various neurological conditions, including migraines and cluster headaches.
electroCore, a bioelectronic medicine company, announced promising results from a pre-clinical trial investigating the use of gammaCore (nVNS) for treating Traumatic Brain Injury (TBI). Presented at the NCS Annual Meeting, the study showed that nVNS significantly reduced brain lesion size by up to 89% and improved neurobehavioral outcomes in rodent models. The company received a grant from NINDS to further explore nVNS's effects on TBI. Notably, TBI affects millions annually in the U.S. with immense healthcare costs, highlighting the potential impact of this research.